Sign inJoin waitlistJoin the waitlist

Garrett Wasp

Assistant Professor of Medicine · Geisel School of Medicine

Credentials: · · · · ·

History

The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth College
2021
Hematology and Medical Oncology
Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
2016–2019
Internal Medicine
Dartmouth Hitchcock Medical Center
2013–2016
SUNY - The State University of New York Upstate Medical University College of Medicine
2013

Research

End-of-life quality metrics among medicare decedents at minority-serving cancer centers: A retrospective study
Cancer Medicine · 2020 · First of 8 authors · Corresponding · 38 citations
User-Centered Design of the consideRATE Questions, a Measure of People's Experiences When They Are Seriously Ill
Review · Journal of Pain and Symptom Management · 2021 · 18 citations
Implementation and Impact of a Serious Illness Communication Training for Hematology-Oncology Fellows
Journal of Cancer Education · 2021 · First of 6 authors · Corresponding · 17 citations

Amber Barnato
8 papers
Amelia Cullinan
6 papers
Maxwell Vergo
5 papers
Gabriel Brooks
4 papers
Kathryn Kirkland
4 papers
Meredith MacMartin
3 papers
CA
Catherine Anton
2 papers
Matthew Wilson
2 papers
Nirav Kapadia
2 papers
Aarti Bhatia
1 paper
Alexandra Kejner
1 paper
Barbara Burtness
1 paper

Grants

Developing and Testing an Interactive Visual Aid for Approaching Decision Making to Stop Cancer Treatment in Advanced Cancer
National Cancer Institute · K08
Contact PI · $772.2K · Dartmouth-Hitchcock Clinic
2024–2029

Clinical trials

Developing an Experimental Framework to Evaluate Oncologist Emotion Regulation
Principal investigator · Completed
Dartmouth-Hitchcock Medical Center
2020–2021
Emotion Regulation and Burnout Impact on Communication Documentation
Principal investigator · Withdrawn
Dartmouth-Hitchcock Medical Center
2019–2022
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2032